Agenus (AGEN) Projected to Post Quarterly Earnings on Monday

Key Points

• Agenus is set to release its Q2 2025 earnings on Monday, August 11th, with analysts expecting a loss of ($0.78) per share and revenue of $49.71 million.
• The company's stock traded up to $5.48, with a market capitalization of $150.21 million, and a year range of $1.38 to $7.34.
• Recent analyst upgrades include a boost from HC Wainwright, who raised the rating from "neutral" to "buy" with a target price of $25.00.

Agenus (NASDAQ:AGEN - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Monday, August 11th. Analysts expect Agenus to post earnings of ($0.78) per share and revenue of $49.71 million for the quarter.

Agenus (NASDAQ:AGEN - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($1.03) EPS for the quarter, beating analysts' consensus estimates of ($1.61) by $0.58. The business had revenue of $24.07 million for the quarter, compared to analyst estimates of $26.38 million. On average, analysts expect Agenus to post $-13 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Agenus Price Performance

Agenus stock traded down $0.13 during midday trading on Friday, reaching $4.63. The company had a trading volume of 152,447 shares, compared to its average volume of 837,453. Agenus has a 12-month low of $1.38 and a 12-month high of $7.34. The company has a market capitalization of $127.02 million, a P/E ratio of -0.53 and a beta of 1.62. The firm's fifty day simple moving average is $5.39 and its 200-day simple moving average is $3.66.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AGEN. Invesco Ltd. acquired a new stake in shares of Agenus in the first quarter valued at approximately $88,000. AQR Capital Management LLC grew its holdings in Agenus by 3,080.3% in the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company's stock valued at $664,000 after buying an additional 427,604 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in shares of Agenus in the 1st quarter worth $58,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AGEN has been the subject of a number of research analyst reports. HC Wainwright raised Agenus from a "neutral" rating to a "buy" rating and set a $25.00 target price for the company in a report on Wednesday, June 4th. B. Riley reissued a "buy" rating on shares of Agenus in a research note on Monday, April 21st. Wall Street Zen raised shares of Agenus from a "strong sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Robert W. Baird upped their target price on shares of Agenus from $4.00 to $6.00 and gave the stock a "neutral" rating in a report on Wednesday, June 4th.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.